Maria Grazia Piccioni1, Carmela Capone2, Flaminia Vena1, Valentina Del Negro1, Michele Carlo Schiavi1, Valentina D'Ambrosio1, Antonella Giancotti1, Maria Paola Smacchia3, Roberto Brunelli1. 1. Department of Gynecological and Obstetric Sciences and Urological Sciences, University of Rome "Sapienza", Umberto I Hospital, V. le del Policlinico 155, 00161 Rome, Italy. 2. Department of Gynecological and Obstetric Sciences and Urological Sciences, University of Rome "Sapienza", Umberto I Hospital, V. le del Policlinico 155, 00161 Rome, Italy. Electronic address: carmela.capone@uniroma1.it. 3. Department of Pediatrics and Child Neuropsychiatry, University of Rome "Sapienza", Umberto I Hospital, V. le del Policlinico 155, 00161 Rome, Italy.
Abstract
OBJECTIVE: To report cases of use of chelation therapy during pregnancy which resulted in favorable outcomes for the babies. MATERIALS AND METHODS: In this retrospective cohort study, we described the evolution and outcome of 9 pregnancies in Italian thalassemic women who received deferoxamine (DFO) inadvertently during early pregnancy. RESULTS: The use of deferoxamine during first trimester did not lead to adverse effects on the fetus or cause major complications for the gestation, although an increase in iron burden was observed after suspending chelation therapy. CONCLUSION: In our experience, iron-chelation therapy might be administrated in pregnancy where the benefits to the mother outweigh the potential risks to the baby.
OBJECTIVE: To report cases of use of chelation therapy during pregnancy which resulted in favorable outcomes for the babies. MATERIALS AND METHODS: In this retrospective cohort study, we described the evolution and outcome of 9 pregnancies in Italian thalassemic women who received deferoxamine (DFO) inadvertently during early pregnancy. RESULTS: The use of deferoxamine during first trimester did not lead to adverse effects on the fetus or cause major complications for the gestation, although an increase in iron burden was observed after suspending chelation therapy. CONCLUSION: In our experience, iron-chelation therapy might be administrated in pregnancy where the benefits to the mother outweigh the potential risks to the baby.